BioPharmSignal logoBioPharmSignal

Biotech News

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

MacroGenics (MGNX)MacroGenicsCompany update

ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside

Open original release

Related news

MGNXMacroGenics2026-05-11 21:20 EST

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

KURAKura Oncology2026-05-06 11:30 EST

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

FATEFate Therapeutics2026-06-01 12:30 EST

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

View all latest news

MacroGenics

MacroGenics is an oncology company focused on engineered antibodies and targeted cancer therapies. The company has long been known for antibody engineering and immuno-oncology programs.

Recent company news

MGNXMacroGenics2026-05-14 20:01 EST

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

MGNXMacroGenics2026-05-11 21:20 EST

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

MGNXMacroGenics2026-05-04 11:30 EST

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

MGNXMacroGenics2026-04-08 20:30 EST

FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study

Stock data

Close
4.00 USD
Market cap
257.43M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States